Shavadia JS, et al. - In order to clearly determine the advantage of β-blocker use beyond 3 years following a myocardial infarction (MI), researchers analyzed patients ≥65 years of age with MI, discharged on β-blocker therapy and alive 3 years later without a recurrent MI in this observational analysis. They linked data from the CRUSADE Registry (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) to Medicare claims, to assess β-blocker use and dose (none, <50%, and ≥50% of the recommended target) at 3 years. Findings revealed no link between β-blocker use beyond 3 years after MI and improved outcomes, this was noted irrespective of the dose achieved. There is a need for further exploration of the role of prolonged β-blocker use, especially in older adults.